10,689,452 Shares in Palisade Bio, Inc. $PALI Acquired by Jupiter Topco LLC

Jupiter Topco LLC purchased a new position in shares of Palisade Bio, Inc. (NASDAQ:PALI) during the 2nd quarter, HoldingsChannel.com reports. The fund purchased 10,689,452 shares of the company’s stock, valued at approximately $22,394,000. Jupiter Topco LLC owned about 0.06% of Palisade Bio as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Total Clarity Wealth Management Inc. acquired a new stake in Palisade Bio during the fourth quarter worth about $70,000. Jefferies Financial Group Inc. acquired a new position in Palisade Bio in the 4th quarter valued at about $110,000. Geode Capital Management LLC boosted its holdings in Palisade Bio by 5,780.7% in the 4th quarter. Geode Capital Management LLC now owns 1,565,452 shares of the company’s stock valued at $3,681,000 after purchasing an additional 1,538,832 shares during the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of Palisade Bio in the 4th quarter valued at approximately $1,310,000. Finally, TD Asset Management Inc purchased a new stake in shares of Palisade Bio in the 4th quarter valued at approximately $480,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

Palisade Bio Stock Performance

Palisade Bio stock opened at $2.00 on Friday. The company has a market capitalization of $348.54 million, a PE ratio of -4.17 and a beta of 1.52. Palisade Bio, Inc. has a fifty-two week low of $0.53 and a fifty-two week high of $2.86. The firm has a 50 day moving average price of $2.02 and a 200 day moving average price of $1.95.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). The firm had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.50 million. As a group, equities research analysts forecast that Palisade Bio, Inc. will post -0.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on PALI shares. LADENBURG THALM/SH SH raised Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. Wall Street Zen raised Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Oppenheimer assumed coverage on shares of Palisade Bio in a report on Thursday, July 23rd. They issued an “outperform” rating and a $8.00 price objective on the stock. Weiss Ratings cut shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $2.00 target price on shares of Palisade Bio in a research report on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Palisade Bio currently has an average rating of “Buy” and an average target price of $9.00.

Insider Activity at Palisade Bio

In other news, Director Robert Jr. Baltera bought 25,000 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was bought at an average cost of $1.96 per share, with a total value of $49,000.00. Following the transaction, the director directly owned 461,904 shares in the company, valued at $905,331.84. The trade was a 5.72% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO John David Finley sold 146,798 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $2.07, for a total transaction of $303,871.86. Following the sale, the chief executive officer owned 217,555 shares in the company, valued at $450,338.85. This trade represents a 40.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have bought 125,000 shares of company stock worth $250,100. 0.07% of the stock is currently owned by company insiders.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.